Case Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Case Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).
Case Comprehensive Cancer Center: 407 sponsored US clinical trials, 55 recruiting.
Case Comprehensive Cancer Center sponsors 407 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 257 completed. 13 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
Case Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
257 of 325 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
407 total, page 3 of 9
Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites
NCT04474613
Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer
NCT04357587
Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N
NCT04323202
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
NCT04187833
C-FLASH (Cigarillo Flavor and Abuse Liability, Attention, and Substitution in youtH)
NCT04358705
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
NCT04322643
Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies
NCT04332419
Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma
NCT04248244
Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery
NCT04176419
Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
NCT04140292
Building Family Caregiver Skills Using a Simulation-Based Intervention for Care of Cancer Patients
NCT04055948
DRIHNC - Dehydration Reduction in Head & Neck Cancer
NCT03799380
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
NCT05079113
Incomplete Follow Up After Positive FIT or Stool DNA Testing: A Multimethod Approach
NCT03817905
Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC
NCT03818776
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
NCT04051606
CPX-351 Therapy for MDS After Hypomethylating Agent Failure
NCT03957876
Improving Sexual Health in Gynecologic Cancer Patients
NCT03827993
18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis
NCT03930173
Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification
NCT03603925
Feasibility of a Culturally-Specific Video Text Cessation Intervention With AA Quitline Callers
NCT03927976
Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity
NCT04245150
Prehabilitation in Pancreatic Surgery
NCT03688867
Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans
NCT03640208
Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer
NCT03650803
Innovations to Prevent Relapse Among Low-income African American Smokers
NCT03982576
Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma
NCT03768856
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
NCT03535363
Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma
NCT03467789
Improved Intra-operative Safety From Optimal Selection of Anti-slip Surface
NCT03573557
Intra-procedural 360-degree Display for Performing Percutaneous Liver Tumor Ablation
NCT03500757
Path2Quit Tobacco Intervention For African Americans
NCT03524482
Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation
NCT03342196
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
NCT03397173
A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
NCT02978586
Endoesophageal Brachytherapy for Patients With Esophageal Cancer
NCT03335813
3D Printed Models in Mohs Micrographic Surgery
NCT03461965
Music Therapy and Hematopoietic Stem Cell Transplant
NCT03378089
Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening
NCT03387527
Debulking Surgery in Ovarian Cancer
NCT03378128
End Nicotine Dependence Clinic
NCT03290430
Getting Ahead for Cancer Control
NCT03247634
Feasibility of a Social Media-based Weight Loss Program for Low Socioeconomic Status Individuals
NCT03337230
Utilizing the Arts to Improve Health, Resilience, and Well-Being Among Cancer Patients and Their Caregivers
NCT03272880
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
NCT03290417
Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas
NCT02970448
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
NCT03126331
Evaluating the Impact of Video Discharge Instructions for Mohs Surgery Post-Operative Care
NCT02970435
Efficacy of Digital Breast Tomosynthesis + Standard 2- Dimensional Mammography in Breast Cancer
NCT03190083
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
NCT02658097
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 116 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Case Comprehensive Cancer Center pipeline
55 recruiting of 407 indexed (14% open); 257 completed (63%).
Phase mix: 13 late (III/IV) vs 203 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Case Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 407 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Case Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 407 trials (± recruiting share)
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Beth Israel Deaconess Medical Center · 14% recruiting · 488 trials
- Wayne State University · 13% recruiting · 163 trials
- University of Michigan · 13% recruiting · 1,327 trials
- Albany Medical College · 13% recruiting · 52 trials
Related
What to do with this Case Comprehensive Cancer Center page
407 registered trials is a research-attention snapshot, not an endorsement of Case Comprehensive Cancer Center or any single study.
- 55 of Case Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Case Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Case Comprehensive Cancer Center pipeline card: 407 registered trials from official public datasets.Report a data error.